Terns Pharmaceuticals, Inc.
TERN
$52.63
$0.070.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.50% | 3.51% | -14.22% | -13.43% | -18.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.10% | 8.50% | -2.33% | 0.00% | -0.67% |
| Operating Income | -8.10% | -8.50% | 2.33% | 0.00% | 0.67% |
| Income Before Tax | -7.94% | -7.28% | 4.33% | 0.71% | 1.53% |
| Income Tax Expenses | 123.46% | -11.52% | -4.15% | -9.06% | 8.79% |
| Earnings from Continuing Operations | -8.28% | -7.22% | 4.33% | 0.73% | 1.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.28% | -7.22% | 4.33% | 0.73% | 1.50% |
| EBIT | -8.10% | -8.50% | 2.33% | 0.00% | 0.67% |
| EBITDA | -8.35% | -8.71% | 2.25% | -0.01% | 0.70% |
| EPS Basic | 8.26% | 12.44% | 20.36% | 13.56% | 10.99% |
| Normalized Basic EPS | 8.52% | 12.39% | 20.36% | 13.53% | 11.02% |
| EPS Diluted | 8.26% | 12.44% | 20.36% | 13.56% | 10.99% |
| Normalized Diluted EPS | 8.52% | 12.39% | 20.36% | 13.53% | 11.02% |
| Average Basic Shares Outstanding | 17.22% | 22.40% | 20.29% | 15.66% | 11.55% |
| Average Diluted Shares Outstanding | 17.22% | 22.40% | 20.29% | 15.66% | 11.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |